We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+14.61%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$51.6B
AUM Growth
+$5.68B
Cap. Flow
-$429M
Cap. Flow %
-0.83%
Top 10 Hldgs %
17.19%
Holding
3,020
New
40
Increased
1,307
Reduced
1,586
Closed
73

Top Buys

Rank Stock Value
1
DIS icon
Walt Disney
DIS
+$73.8M
2
AMZN icon
Amazon
AMZN
+$68.6M
3
AAPL icon
Apple
AAPL
+$64.9M
4
MSFT icon
Microsoft
MSFT
+$61.4M
5
META icon
Meta Platforms (Facebook)
META
+$30.9M

Sector Composition

Rank Sector Weight
1 Technology 18.09%
2 Financials 15.13%
3 Healthcare 13.65%
4 Consumer Discretionary 10.39%
5 Industrials 10.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AMRS
2876
DELISTED
Amyris Inc.
AMRS
$88K ﹤0.01%
42,265
+153
+0.4% +$604
SREV
2877
DELISTED
ServiceSource International, Inc.
SREV
$88K ﹤0.01%
96,018
-525
-0.5% -$550
ADMA icon
2878
ADMA Biologics
ADMA
$2.15B
$86K ﹤0.01%
22,799
-480
-2% -$1.7K
DWSN icon
2879
Dawson Geophysical
DWSN
$137M
$86K ﹤0.01%
29,510
-45
-0.2% -$161
COGT icon
2880
Cogent Biosciences
COGT
$7.23B
$85K ﹤0.01%
+4,868
New +$83.2K
TPHS
2881
DELISTED
Trinity Place Holdings Inc.com
TPHS
$83K ﹤0.01%
20,709
-435
-2% -$1.82K
MTEM
2882
DELISTED
Molecular Templates, Inc.
MTEM
$83K ﹤0.01%
949
+74
+8% +$5.42K
NYMX
2883
DELISTED
Nymox Pharmaceutical Corp
NYMX
$83K ﹤0.01%
42,145
-415
-1% -$880
RNAC icon
2884
Cartesian Therapeutics
RNAC
$246M
$81K ﹤0.01%
1,139
+346
+44% +$21.9K
VHI icon
2885
Valhi
VHI
$408M
$80K ﹤0.01%
2,904
-14
-0.5% -$520
FBIO icon
2886
Fortress Biotech
FBIO
$93.3M
$79K ﹤0.01%
2,953
-56
-2% -$1.47K
LUMO
2887
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$79K ﹤0.01%
4,536
+49
+1% +$731
NWHM
2888
DELISTED
THE NEW HOME COMPANY INC.
NWHM
$79K ﹤0.01%
16,689
-60
-0.4% -$359
NTGN
2889
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
$78K ﹤0.01%
+12,058
New +$63.1K
ROX
2890
DELISTED
Castle Brands, Inc.
ROX
$78K ﹤0.01%
111,440
-2,235
-2% -$1.86K
FRE
2891
DELISTED
FREDDIE MAC D/B/A VOTING
FRE
$78K ﹤0.01%
28,948
-30,035
-51% -$80.9K
NCSM icon
2892
NCS Multistage Holdings
NCSM
$124M
$74K ﹤0.01%
711
-4
-0.6% -$443
ECOR icon
2893
electroCore
ECOR
$56.5M
$73K ﹤0.01%
+694
New +$74.5K
ELGX
2894
DELISTED
Endologix Inc
ELGX
$73K ﹤0.01%
11,014
+316
+3% +$2.08K
CRVS icon
2895
Corvus Pharmaceuticals
CRVS
$1.17B
$72K ﹤0.01%
17,853
-350
-2% -$1.48K
KG
2896
Kestrel Group
KG
$70.1M
$71K ﹤0.01%
4,789
-5,105
-52% -$118K
NEXT icon
2897
NextDecade
NEXT
$1.71B
$70K ﹤0.01%
12,715
-200
-2% -$834
ACET icon
2898
Adicet Bio
ACET
$85.3M
$69K ﹤0.01%
+90
New +$81.8K
LLEX
2899
DELISTED
Lilis Energy, Inc. Common Stock
LLEX
$69K ﹤0.01%
58,716
-323
-0.5% -$558
APTX
2900
DELISTED
Aptinyx Inc. Common Stock
APTX
$67K ﹤0.01%
16,619
-325
-2% -$2.35K

Similar funds

RhumbLine Advisers's Q1 2019 Portfolio in Review

As of Q1 2019, RhumbLine Advisers held 3,020 positions worth $51.6B, up 12% from $46B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Trading was light in Q1 2019: portfolio turnover was 3.7%. RhumbLine Advisers opened 40 new positions and exited 73, leaving the 3,020-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.

  • RhumbLine Advisers's largest Q1 2019 buy was Fox Class A: 602,636 shares worth $22.1M.
  • RhumbLine Advisers added most to Walt Disney in Q1 2019, an estimated $73.8M increase.
  • RhumbLine Advisers's biggest Q1 2019 reduction was Wells Fargo, cutting an estimated $16.4M.
  • RhumbLine Advisers fully exited Twenty-First Century Fox, Inc. Class A in Q1 2019, selling an estimated $89.7M.
  • RhumbLine Advisers's ten largest holdings make up 17% of its $51.6B portfolio in Q1 2019.
  • RhumbLine Advisers opened 40 new positions and closed 73 in Q1 2019.
  • RhumbLine Advisers's portfolio value rose 12% quarter-over-quarter to $51.6B.

Based on RhumbLine Advisers's 13F filing for Q1 2019, filed 1 May 2019.